The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock

The scientific rationale and study protocol for the DPP3, Angiotensin II, and Renin Kinetics in Sepsis (DARK-Sepsis) randomized controlled trial: serum biomarkers to predict response to angiotensin II versus standard-of-care vasopressor therapy in the treatment of septic shock

Abstract Background Data to support the use of specific vasopressors in septic shock are limited. Since angiotensin II (AT2) was approved by the Food and Drug Administration in 2017, multiple mechanistically distinct vasopressors are available to treat septic shock, but minimal data exist regarding...

Full description

Bibliographic Details
Main Authors: J. Pedro Teixeira, David Perez Ingles, Jordan B. Barton, James T. Dean, Pablo Garcia, Susan J. Kunkel, Preeyaporn Sarangarm, Natalie K. Weiss, Christopher L. Schaich, Laurence W. Busse, Nathan D. Nielsen
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Trials
Subjects:
Septic shock
Angiotensin II
Vasopressor
Renin
Biomarker
Dipeptidyl-peptidase 3
Online Access:https://doi.org/10.1186/s13063-024-07995-0

Internet

https://doi.org/10.1186/s13063-024-07995-0

Similar Items